Conceptos actuales | 18 MAR 13

Tuberculosis: ¿Qué hay que saber hoy?

A pesar de un tratamiento barato y efectivo, la tuberculosis sigue generando millones de casos de enfermedad activa y muertes en todo el mundo.
Autor: Dres. Alimuddin Zumla, Mario Raviglione, Richard Hafner, C. Fordham von Reyn N Engl J Med 2013;368:745-55.
INDICE:  1. Artículo | 2. Referencias

1. Global tuberculosis report 2012. Geneva: World Health Organization (
2. Zignol M, van Gemert W, Falzon D, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull World Health Organ 2012;90:111D-119D.
3. Tuberculosis MDR-TB and XDR-TB: 2011 progress report. Geneva: World Health Organization, 2011 (http://www
4. Hill AN, Becerra J, Castro KG. Modelling
tuberculosis trends in the USA. Epidemiol Infect 2012;140:1862-72.
5. Surveillance report: tuberculosis surveillance and monitoring in Europe 2012 Geneva: World Health Organization (
6. Abubakar I, Lipman M, Anderson C, Davies P, Zumla A. Tuberculosis in the UK — time to regain control. BMJ 2011;343:d4281.
7. Ewer K, Millington KA, Deeks JJ, Alvarez
L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006;174:831-9.
8. Andrews JR, Noubary F, Walensky RP, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012;54:784-91.
9. Verver S, Warren RM, Beyers N, et al.
Rate of reinfection tuberculosis after successful
treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005;171:1430-5.
10. Lahey T, Mackenzie T, Arbeit RD, et al. Recurrent tuberculosis risk among HIVinfected adults in Tanzania with prior active tuberculosis. Clin Infect Dis 2013;56:151-8.
11. Frieden TR, Munsiff SS, Ahuja SD. Outcomes of multidrug-resistant tuberculosis treatment in HIV-positive patients in New York City, 1990-1997. Int J Tuberc Lung Dis 2007;11:116.
12. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.
13. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-807.
14. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012;54:579-81.
15. “Totally Drug-Resistant TB”: a WHO consultation on the diagnostic definition and treatment options. Geneva: World Health Organization (http://www.who .int/tb/challenges/xdr/Report_Meeting_totallydrugresistantTB_032012.pdf).
16. Nathanson E, Nunn P, Uplekar M, et al. MDR tuberculosis — critical steps for prevention and control. N Engl J Med 2010;363:1050-8.
17. Lawn SD, Zumla AI. Tuberculosis. Lancet 2011;378:57-72.
18. Caws M, Thwaites G, Dunstan S, et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008;4(3):e1000034.
19. von Reyn CF. Optimal treatment of codisease due to HIV and tuberculosis. J Infect Dis 2011;204:817-9.
20. von Reyn CF, Kimambo S, Mtei L, et al. Disseminated tuberculosis in human immunodeficiency virus infection: ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 2011;15:1087-92.
21. Mudenda V, Lucas S, Shibemba A, et al. Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies. J Infect Dis 2012;205:Suppl 2:S340-S346.
22. Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005;40:1500-7.
23. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010;362:707-16.
24. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data metaanalysis of observational studies. PLoS Med 2011;8(1):e1000391.
25. Bates M, O’Grady J, Mwaba P, et al. Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatients. PLoS One 2012;7(7):e40774.
26. Horsburgh CR Jr, Rubin EJ. Latent tuberculosis infection in the United States. N Engl J Med 2011;364:1441-8.
27. Ferrara G, Murray M, Winthrop K, et al. Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs. Curr Opin Pulm Med 2012;18:233-40.
28. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection —United States, 2010. MMWR Morb Mortal
Wkly Rep 2010;59:1-25.
29. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence, 2011 (http://www
30. Use of interferon-gamma release assays in support of TB diagnosis. Stockholm: European Centre for Disease Prevention and Control, 2011 (http://ecdc
31. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 2012;205:Suppl 2:S147-S58.
32. von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001;5:1122-8.
33. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC. International standards for tuberculosis care. Lancet Infect Dis 2006;6:710-25.
34. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005-15.
35. Lawn SD, Kerkhoff AD, Vogt M, et al. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012;54:1071-9.
36. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization, 2008 (
37. Ling DI, Zwerling AA, Pai M. Geno- Type MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a metaanalysis. Eur Respir J 2008;32:1165-74.
38. O’Grady J, Maeurer M, Mwaba P, et al. New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Curr Opin Pulm Med 2011;17:134-41.
39. Performance of Xpert MTB/RIF version G4 assay. Geneva: Foundation for Innovative New Diagnostics, 2011 (http://www
40. Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational ‘how-to’: practical considerations. Geneva: World Health Organization, 2011 ( .pdf).
41. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006;355:1539-50.
42. WHO policy on collaborative TB/HIV activities. Geneva: World Health Organization, 2012 (
43. Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011;365:11-20.
44. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization, 2011 (
45. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66.
46. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010;1:CD000171.
47. Samandari T, Agizew TB, Nyirenda S, et al. 6-Month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:1588-98.
48. Lawn SD, Wood R. Antiretroviral therapy for control of the HIV-associated MDR and XDR tuberculosis epidemic in South Africa. Am J Respir Crit Care Med 2010;182:1567.
49. Combs DL, O’Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity and acceptability: the report of the final results. Ann Intern Med 1990;112:397-406.
50. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365:1492-501.
51. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011;365:1482-91.
52. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81.
53. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012;157:313-24.
54. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011;53:716-24.
55. Rifampin- based tuberculosis treatment versus rifabutinbased tuberculosis treatment in HIV (
56. Idem. Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment (PrOMPT) (
57. Idem. REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment (http://clinicaltrials .gov/ct2/show/NCT01380080).
58. Guidelines for the programmatic management of drug resistant tuberculosis. Geneva: World Health Organization, 2011 (
59. Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38:516-28.
60. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardized regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004;8:560-7.
61. STREAM: the evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drugresistant tuberculosis (MDR-TB). 2011
62. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data metaanalysi of 9,153 patients. PLoS Med 2012;9(8):e1001300.
63. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
64. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug- resistant tuberculosis. N Engl J Med 2009;360:2397-405.
65. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012;366:2151-60.
66. Diacon AH, Dawson R, von Groote- Bidlingmaier F, et al. 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012;380:986-93.
67. Lee M, Lee J, Carroll MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med 2012;367:1508-18.
68. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702.
69. Stop TB Partnership. Tuberculosis vaccine candidates — 2011 (
70. von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated wholecellmycobacterial vaccine. AIDS 2010;24:675-85.
71. Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 2012;379:1902-13. [Erratum, Lancet 2012;379:2242.]



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Los más...
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2017